Correlation Between Zomedica Pharmaceuticals and Emergent Biosolutions

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Zomedica Pharmaceuticals and Emergent Biosolutions at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zomedica Pharmaceuticals and Emergent Biosolutions into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Zomedica Pharmaceuticals Corp and Emergent Biosolutions, you can compare the effects of market volatilities on Zomedica Pharmaceuticals and Emergent Biosolutions and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zomedica Pharmaceuticals with a short position of Emergent Biosolutions. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zomedica Pharmaceuticals and Emergent Biosolutions.

Diversification Opportunities for Zomedica Pharmaceuticals and Emergent Biosolutions

-0.24
  Correlation Coefficient

Very good diversification

The 3 months correlation between Zomedica and Emergent is -0.24. Overlapping area represents the amount of risk that can be diversified away by holding Zomedica Pharmaceuticals Corp and Emergent Biosolutions in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Emergent Biosolutions and Zomedica Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zomedica Pharmaceuticals Corp are associated (or correlated) with Emergent Biosolutions. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Emergent Biosolutions has no effect on the direction of Zomedica Pharmaceuticals i.e., Zomedica Pharmaceuticals and Emergent Biosolutions go up and down completely randomly.

Pair Corralation between Zomedica Pharmaceuticals and Emergent Biosolutions

Considering the 90-day investment horizon Zomedica Pharmaceuticals Corp is expected to generate 0.53 times more return on investment than Emergent Biosolutions. However, Zomedica Pharmaceuticals Corp is 1.89 times less risky than Emergent Biosolutions. It trades about -0.22 of its potential returns per unit of risk. Emergent Biosolutions is currently generating about -0.16 per unit of risk. If you would invest  14.00  in Zomedica Pharmaceuticals Corp on September 13, 2024 and sell it today you would lose (2.00) from holding Zomedica Pharmaceuticals Corp or give up 14.29% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Zomedica Pharmaceuticals Corp  vs.  Emergent Biosolutions

 Performance 
       Timeline  
Zomedica Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Zomedica Pharmaceuticals Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Zomedica Pharmaceuticals is not utilizing all of its potentials. The newest stock price disarray, may contribute to short-term losses for the investors.
Emergent Biosolutions 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Emergent Biosolutions are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain fundamental drivers, Emergent Biosolutions unveiled solid returns over the last few months and may actually be approaching a breakup point.

Zomedica Pharmaceuticals and Emergent Biosolutions Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Zomedica Pharmaceuticals and Emergent Biosolutions

The main advantage of trading using opposite Zomedica Pharmaceuticals and Emergent Biosolutions positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zomedica Pharmaceuticals position performs unexpectedly, Emergent Biosolutions can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will offset losses from the drop in Emergent Biosolutions' long position.
The idea behind Zomedica Pharmaceuticals Corp and Emergent Biosolutions pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Complementary Tools

Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
CEOs Directory
Screen CEOs from public companies around the world
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.